iFondaparinSodium;Uchongo lweFondaparinux Sodium;Fondaparinux sodium N-4;
iFondaparinSodium;Uchongo lweFondaparinux Sodium;Fondaparinux sodium N-4;
Fondaparinux Biological Activity
| Chaza | I-Fondaparinux sodium yi-antithrombin-dependent factor Xa inhibitor. |
| EyeleleneyoIindidi | indlela yomqondiso >> Metabolic enzymes/proteases >> Factor Xa Iindawo zophando >> Izifo zentliziyo |
| Ekujoliswe kuko | Factor Xa[1] |
| I-In vitroizifundo | I-Fondaparinux i-sodium yi-anticoagulant yokuqala entsha ejolise ngokukhethekileyo kwi-factor Xa.Kwi-Fondaparinux, ixabiso le-IC50 (i-anti-Xa IU/ml) ye-monocytes esebenzayo (ac-M) yi-0.59±0.05, kunye ne-monocyte-derived particles (MMP) yi-0.17±0.03 [2]. |
| Kwi-vivouphando | I-Fondaparinux sodium ine-linear, iprofayili ye-pharmacokinetic exhomekeke kwidosi, enika impendulo eqikelelweyo kakhulu.I-Fondaparinux sodium ine-100% ye-bioavailability, inokuqala ngokukhawuleza kwesenzo, inesiqingatha sobomi be-14 kwiiyure ze-16, kwaye inokuqhubeka nokumelana ne-thrombosis kwiiyure ezingama-24.Ichiza alichaphazeli ixesha leprothrombin okanye ixesha le-thromboplastin elisebenzayo, kwaye alichaphazeli ukusebenza kweplatelet okanye ukuhlanganiswa [1]. |
| Iimbekiselo | [1].Bauer KA.okqhubekayo.I-Fondaparinux sodium: inhibitor ekhethiweyo ye-factor Xa.Am J Health Syst Pharm.2001 Nov 1;58 Suppl 2:S14-7.[2].UBen-Hadj-Khalifa S, et al.Ukwahlukana kwe-coagulation inhibitory effect ye-fondaparinux, i-enoxaparin kunye ne-heparin engaxutywanga kwiimodeli zeeseli zesizukulwana se-thrombin.Igazi le-Coagul Fibrinolysis.2011 Jul;22(5):369-73. |
Iimpawu zeMichiza kunye nezomzimba zeFondaparinux
| Ifomula yemolekyuli | C31H53N3Na10O49S8 |
| Ubunzima bemolekyuli | 1738.16 |
| PSA | 900.82000 |
I-Fondaparinux luhlobo olutsha lwechiza le-antithrombotic elivunywe yi-FDA emva kwe-heparin kunye ne-heparin ephantsi ye-molecular weight kunyango kunye nokuthintela iintlobo ezahlukeneyo ze-arteriovenous thrombosis.
Izibonakaliso: I-Fondaparinux isetyenziselwa izigulane ezenza utyando olukhulu lwamathambo emilenze ephantsi, njengokuphuka kwe-hip, utyando olukhulu lwamadolo okanye ukutshintshwa kwe-hip, ukukhusela i-thromboembolism ye-venous.Isetyenziselwa unyango lwezigulane ezine-angina engazinzanga okanye i-non-ST-segment elevation myocardial infarction ehamba ngokukhawuleza (<120 imizuzu) unyango olungenayo (PCI) ngaphandle kokubonisa.Isetyenziselwa unyango lwezigulane ezine-ST-segment elevation myocardial infarction abasebenzisa i-thrombolysis okanye ekuqaleni abafumani ezinye iindlela zonyango zonyango.
1）Intengiso eqhubekayo ye-Glaxo yemarike iya kuyibeka kwindawo engundoqo yechiza kwindlela elandelayo yezonyango yoMphathiswa wezeMpilo, uhlaziyo lwexabiso leKomishoni yoPhuhliso noHlengahlengiso lweSizwe, kunye ne-inshurensi yezonyango yoBuphathiswa be-Inshurensi yaBantu.
A, Imveliso ayikangeni kwi-inshurensi yezonyango yesizwe.Ngo-2010, uhlengahlengiso lwe-inshorensi yezonyango lusanda kungena kwi-inshurensi yezonyango yasekuhlaleni yamaphondo ali-16.Iintengiso zikwinqanaba lokuqala kwaye ngokuthe ngcembe ziya kuthatha indawo yemarike ye-heparin ephantsi-molekyuli;amaphondo inshorensi yezonyango: Shaanxi, Shanxi, Inner Mongolia, Liaoning, Tibet, Yunnan, Guangdong , Guangxi, Hainan, Jiangsu, Gansu, Fujian, Jiangxi, Henan, Hubei, Beijing.
B, Iimpawu zisakhula.I-GSK okwangoku inezalathisi ezi-3 ekliniki.Ngokomzekelo, iimpawu ze-stents zivunyiwe kuphela.Ezinye iiheparin azikho.Ukusetyenziswa kweklinikhi ye-stents kwandisa ngama-30% ngonyaka.Ngokuvunywa kwezibonakaliso ezintsha, ukuthengisa kuya kwanda.Kwithiyori, zonke izifo eziphathwa yimveliso ye-heparin zinganyangwa yile mveliso.
C, Ixabiso inzuzo, ixabiso elisezantsi le mveliso kwimarike US 132 US dollar ngalinye, e China yi 168 yuan, ixabiso lasekhaya akayi kuhla.Ukuba uthumela ngaphandle, imarike yamazwe ngamazwe inendawo ebanzi;
2) Umda wezobuchwephesha uphezulu, izinto eziluhlaza zenziwe ngamanyathelo angama-75, kwaye i-patent iphelile iminyaka emi-5 (inqaku ngo-2014).Ayivunywanga ngabanye abavelisi.I-synthesis inzima kakhulu.Ayizukwenziwa ngaphantsi kweminyaka eli-10.Umjikelo mde, unzima, kwaye utyalo-mali.phezulu.Bambalwa abakhuphisana basekhaya, kwaye abakhuphisana bamazwe angaphandle baneendleko eziphezulu zempahla ekrwada.Injongo yethu kukunciphisa ngokuqhubekayo iindleko zempahla kunye nokubuyisela i-Glaxo kwimveliso yempahla ekrwada.
I-Hengrui Pharmaceuticals Fondaparinux yamkelwe njengomzekelo wokuqala e-China ngo-2018.
I-Guangdong Runxing Biotechnology Co., Ltd. inemveliso yonyaka ye-210 kg ye-fondaparinux sodium ephakathi kwe-N3 ephakathi, eya kufakwa kwi-2018.
IFondaparinux yaphuhliswa kuqala yiMYLAN IRELAND.Okwangoku, iHengrui Pharmaceuticals, iBorui Pharmaceuticals, iHaisco.
JIN DUN Medical uyeIsiqinisekiso se-ISO kwaye sidibana nemigangatho yemveliso ye-GMP, kuqeshwe iingcali zasekhaya nezangaphandle zokwenziwa kweziyobisi ezinamava atyebileyo ukukhokela iR&D yenkampani.
I-TECHNOL OGY I-ADVANTAGES
●Uxinzelelo oluPhezulu lweCatalytic Hydrogenation.Uxinzelelo oluPhezulu lwe-Hydrogenolysis Reaction.I-Cryogenic Reaction (<-78%C)
● I-Aromatic Heterocyclic Synthesis
● Ukusabela ngokutsha
● IsiGqibo seChiral
●Heck, Suzuki,Negishi,Sonogashira .Giignard Reaction
Izixhobo
ILebhu yethu inezixhobo ezahlukeneyo zovavanyo kunye novavanyo, ezifana ne: NMR (Bruker 400M) ,HPLC、chiral-HPLC、LC-MS、LC-MS/MS (API 4000),IR,UV,GC,GC,GC-MS, Chromatography, I-Microwave Synthesizer, i-Parallel Synthesizer, iKhalorimitha yokuSkena okwahlukileyo (DSC), iMicroscope ye-Electron...
R&D Iqela
I-Jindun Medical ineqela labasebenzi abaqeqeshiweyo be-R&D, kwaye iqeshe iingcali ezininzi zokwenziwa kweziyobisi zasekhaya nezangaphandle ukukhokela i-R&D, ukwenza udibaniso lwethu luchaneke ngakumbi kwaye lusebenze kakuhle.
Siye sanceda iinkampani ezininzi eziphezulu zamachiza zasekhaya, ezifanaHansoh, Hengrui kunye ne-HEC Pharm.Apha siza kubonisa inxalenye yazo.
Customization Case One:
Inombolo yeCas: 110351-94-5
Ityala leSibini:
Inombolo yeCas: 144848-24-8
Customization Case Three:
Inombolo yeCas: 200636-54-0
1.Lungiselela abaPhakathi abatsha okanye ii-APIs.Ngokufanayo nokwabelana ngetyala elingasentla, abathengi baneemfuno ze-Intermediates ezithile okanye ii-APIs, kwaye abanakuzifumana iimveliso ezifunekayo kwimarike, ngoko sinokunceda ukwenza ngokwezifiso.
2.Ukuphuculwa kweNkqubo yeeMveliso eziDala.Iqela lethu liya kunceda ukukhulisa nokuphucula imveliso enjalo indlela yokusabela indala, ixabiso lemveliso liphezulu, kwaye ukusebenza kakuhle kuphantsi.Sinokubonelela ngamaxwebhu apheleleyo okuhanjiswa kwetekhnoloji kunye nokuphuculwa kwenkqubo, sincede umthengi kwimveliso esebenzayo.
Ukusuka ekujoliswe kuko ngamachiza ukuya kwi-INDs, iJIN DUN Medical ikubonelelaisitophu esinye sezisombululo ze-R&D ezenzelwe wena.
I-JIN DUN Medical igxininisa ekudaleni iqela elinamaphupha, ukwenza iimveliso ezinesidima, ubuqili, ubukhali, kwaye uphume konke ukuze ube liqabane elithembekileyo kunye nomhlobo wabathengi!
